Latest Breaking News On - Lenalidomide refractory multiple myeloma - Page 1 : comparemela.com

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive.

United statesUniversity of chicagoCiltacabtagene autoleucelSusan bobulskyLisocabtagene maraleucelObecabtagene autoleucelBrexucabtagene autoleucel brexuKarina calzadillaErica jonesIdecabtagene vicleucel ideVendexv pomalidomideExchange commissionAmerican society of clinical oncologyAcalabrutinib and obinutuzumabAdaptive biotechnologies corporation nasdaqEuropean hematology association

Adaptive Biotechnologies Announces Data Supporting the

Adaptive Biotechnologies Announces Data Supporting the
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

University of chicagoUnited statesIdecabtagene vicleucel ideErica jonesSusan bobulskyVendexv pomalidomideObecabtagene autoleucelBrexucabtagene autoleucel brexuLisocabtagene maraleucelKarina calzadillaCiltacabtagene autoleucelAcalabrutinib and obinutuzumabCancer center clinica universidad de navarraExchange commissionAmerican society of clinical oncologyEuropean hematology association

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact: Investor contact: .

United statesRegion flamandeEdmond chanJenni mildonCiltacabtagene autoleucelEuropean commission grants conditional approvalLegend biotech united states incJanssen biotech incDrug administrationAmerican society of clinical oncologyEuropean commissionJanssen cilag internationalChinese company legend biotech to develop investigationalAmerican cancer societyCommittee for orphan medicinal productsJanssen research development

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse .

United statesNew jerseyYing huangHemophagocytic lymphohistiocytosisMedicinal devices agencyJanssen cilag internationalJapan ministry of healthExchange commission onAmerican cancer societyEuropean commissionLegend biotech corporationDrug administrationEuropean medicines agencyJanssen biotech incLegend biotechChief executive officer

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesYing huangMary ann ondishHemophagocytic lymphohistiocytosisJessie yeungMedicinal devices agencyDrug administrationJanssen biotech incJapan ministry of healthExchange commission onJanssen cilag internationalEuropean commissionEuropean medicines agencyLegend biotech corporationAmerican cancer society